

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE {Cardboard box}**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Convenia 80 mg/ml Powder and solvent for solution for injection.

**2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES**

Cefovecin 80 mg/ml (after reconstitution).

**3. PACKAGE SIZE**

1 powder vial and 1 vial with 10.8 ml solvent.  
1 powder vial and 1 vial with 4.45 ml solvent.

**4. TARGET SPECIES**

Dogs and cats.

**5. INDICATION(S)**

**6. ROUTES OF ADMINISTRATION**

Subcutaneous use.

**7. WITHDRAWAL PERIODS**

**8. EXPIRY DATE**

Exp. {mm/yyyy}  
Once reconstituted use within 28 days.  
Use by...

**9. SPECIAL STORAGE PRECAUTIONS**

Store in a refrigerator.  
Do not freeze.  
Store in the original package in order to protect from light.

**10. THE WORDS "READ THE PACKAGE LEAFLET BEFORE USE"**

Read the package leaflet before use.

**11. THE WORDS "FOR ANIMAL TREATMENT ONLY"**

For animal treatment only.

**12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**13. NAME OF THE MARKETING AUTHORISATION HOLDER**

Zoetis UK Limited

**14. MARKETING AUTHORISATION NUMBERS**

Vm 42058/5016

**15. BATCH NUMBER**

Lot {number}

**16. SPECIAL WARNING(S), IF NECESSARY**

**17. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Disposal: read package leaflet.

**18. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

POM-V

Veterinary medicinal product subject to prescription.

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING  
UNITS {Powder vial label}**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Convenia

**2. QUALITATIVE AND QUANTITATIVE PARTICULARS OF THE ACTIVE  
SUBSTANCES**

Cefovecin 852 mg  
Cefovecin 340 mg

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}  
Once reconstituted use within 28 days.  
Use by:

**5. ROUTE(S) OF ADMINISTRATION**

SC.

**6. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**PARTICULARS TO APPEAR ON THE IMMEDIATE LABEL OF THE SOLVENT**

**1. NAME OF THE SOLVENT**

Solvent

**2. CONTENT BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES**

4 ml  
10 ml.

**3. ROUTES OF ADMINISTRATION**

Read the package leaflet before use.

**4. STORAGE CONDITIONS**

-

**5. BATCH NUMBER**

Lot {number}

**6. EXPIRY DATE**

Exp. {mm/yyyy}

**7. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.



**8. NAME OF THE MARKETING AUTHORISATION HOLDER**

{Zoetis logo}

## **PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:**

### **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Convenia 80 mg/ml powder and solvent for solution for injection for dogs and cats

### **2. COMPOSITION**

#### **Active substance:**

Each ml contains 80 mg cefovecin (as sodium salt) after reconstitution.

#### **Excipients:**

##### Lyophilisate:

Methyl parahydroxybenzoate (E218)	1.8 mg/ml.
Propyl parahydroxybenzoate (E216)	0.2 mg/ml.

##### Solvent:

Benzyl alcohol	13 mg/ml.
----------------	-----------

The powder is off-white to yellow and the solvent is a clear, colourless liquid.

### **3. TARGET SPECIES**

Dogs and cats.

### **4. INDICATIONS FOR USE**

For use only for the following infections requiring prolonged treatment. The antimicrobial activity of the veterinary medicinal product following a single injection lasts for up to 14 days.

#### Dogs:

For the treatment of skin and soft tissue infections including pyoderma, wounds and abscesses associated with *Staphylococcus pseudintermedius*,  $\beta$ -haemolytic Streptococci, *Escherichia coli* and/or *Pasteurella multocida*.

For the treatment of urinary tract infections associated with *Escherichia coli* and/or *Proteus* spp.

As adjunctive treatment to mechanical or surgical periodontal therapy in the treatment of severe infections of the gingiva and periodontal tissues associated with *Porphyromonas* spp. and *Prevotella* spp. (see also section 6 'Special Warnings – Special precautions for safe use in the target species').

#### Cats:

For the treatment of skin and soft tissue abscesses and wounds associated with *Pasteurella multocida*, *Fusobacterium* spp., *Bacteroides* spp., *Prevotella oralis*,  $\beta$ -haemolytic Streptococci and/or *Staphylococcus pseudintermedius*.

For the treatment of urinary tract infections associated with *Escherichia coli*.

## 5. CONTRAINDICATIONS

Do not use in cases of hypersensitivity to cephalosporin or penicillin antibiotics or to any of the excipients.

Do not use in small herbivores (including guinea pigs and rabbits).

Do not use in dogs and cats less than 8 weeks old.

## 6. SPECIAL WARNINGS

### Special warnings:

Cross-resistance has been shown between cefovecin and other cephalosporins and other  $\beta$ -lactam antibiotics. Use of the veterinary medicinal product should be carefully considered when susceptibility testing has shown resistance to cephalosporins or  $\beta$ -lactams because its effectiveness may be reduced.

### Special precautions for safe use in the target species:

Use of the product should be based on identification and susceptibility testing of the target pathogen(s). If this is not possible, therapy should be based on epidemiological information and knowledge of susceptibility of the target pathogens at local/regional level. Use of the product should be in accordance with official, national and regional antimicrobial policies.

An antibiotic with a lower risk of antimicrobial resistance selection (lower AMEG category) should be used for first line treatment where susceptibility testing suggests the likely efficacy of this approach.

The product selects for resistant strains such as bacteria carrying extended-spectrum beta-lactamases (ESBL) and may constitute a risk to human health if these strains disseminate to humans.

The fundamental requirement of the treatment of periodontal disease is mechanical and/or surgical intervention by the veterinarian.

The safety of the veterinary medicinal product has not been assessed in animals suffering from severe renal dysfunction.

Pyoderma is often secondary to an underlying disease. It is, therefore, advisable to determine the underlying cause and to treat the animal accordingly.

Caution should be exercised in patients that have previously shown hypersensitivity reactions to cefovecin, other cephalosporins, penicillins, or other medicinal products. If an allergic reaction occurs, no further administrations of cefovecin should be administered and appropriate therapy for beta-lactam hypersensitivity should be instituted. Serious acute hypersensitivity reactions may require treatment with epinephrine and other emergency measures, including oxygen, intravenous fluids,

intravenous antihistamine, corticosteroids, and airway management, as clinically indicated. Veterinarians should be aware that reappearance of the allergic symptoms may occur when symptomatic therapy is discontinued.

Occasionally, cephalosporins have been associated with myelotoxicity, thereby creating a toxic neutropenia. Other haematological reactions seen with cephalosporins include neutropenia, anaemia, hypoprothrombinemia, thrombocytopenia, prolonged prothrombin time (PT) and partial thromboplastin time (PTT), platelet dysfunction.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillins may lead to cross sensitivity to cephalosporins and vice versa. Allergic reactions to these substances may occasionally be serious.

Do not handle this product if you know you are sensitised or if you have been advised not to work with such preparations.

Handle this product with care to avoid exposure, taking all recommended precautions.

If you develop symptoms following exposure, such as a skin rash, you should seek medical advice and show the doctor this warning. Swelling of the face, lips or eyes or difficulty in breathing are more serious symptoms and require urgent medical attention.

If you know you are allergic to penicillins or cephalosporins, avoid contact with contaminated litter. In the event of contact, wash skin with soap and water.

Pregnancy and lactation:

The safety of the veterinary medicinal product in dogs and cats has not been established during pregnancy and lactation.

Fertility:

Treated animals should not be used for breeding for 12 weeks after the last administration.

Interaction with other medicinal products and other forms of interaction:

Concurrent use of other substances that have a high degree of protein binding (e.g. furosemide, ketoconazole, or non-steroidal anti-inflammatory drugs (NSAIDs)) may compete with cefovecin binding and thus may cause adverse events.

Overdose:

Repeated dosing (eight administrations) in 14-day intervals at five times the recommended dose was tolerated well in young dogs. Slight and transient injection

site swellings were observed after the first and second administration. A single administration of 22.5 times the recommended dose caused transient oedema and discomfort at the injection site.

Repeated dosing (eight administrations) in 14-day intervals at five times the recommended dose was tolerated well in young cats. A single administration of 22.5 times the recommended dose caused transient oedema and discomfort at the injection site.

Major incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

## 7. ADVERSE EVENTS

Dogs and cats:

Very rare (<1 animal / 10,000 animals treated, including isolated reports): Injection site reaction, Digestive tract disorder (e.g. diarrhoea, emesis, anorexia), Hypersensitivity reaction (e.g. anaphylaxis, circulatory shock, dyspnoea) <sup>1</sup> , Neurological signs (e.g. ataxia, convulsion, seizure)
---

<sup>1</sup> Appropriate treatment should be administered without delay.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system:

UK only: <https://www.gov.uk/report-veterinary-medicine-problem>.

IE only: [www.hpra.ie](http://www.hpra.ie)

## 8. DOSAGE FOR EACH SPECIES, ROUTES AND METHOD OF ADMINISTRATION

Subcutaneous use.

Dogs and cats: 8 mg cefovecin/kg bodyweight (1 ml of the veterinary medicinal product 10 kg bodyweight).

**Dosing table:**

<b>Animal weight (dogs and cats)</b>	<b>Volume to be administered</b>
2.5 kg	0.25 ml
5 kg	0.5 ml
10 kg	1 ml
20 kg	2 ml
40 kg	4 ml
60 kg	6 ml

To reconstitute, withdraw the required volume of the supplied solvent from its vial (for 23 ml vial containing 978.65 mg of lyophilised powder reconstitute using 10 ml of solvent, or for 5 ml vial containing 390.55 mg of lyophilised powder reconstitute using 4 ml of solvent) and add to the vial containing the lyophilised powder. Shake the vial until the powder is seen to have fully dissolved.

Skin and soft tissue infections in dogs:

A single subcutaneous injection. If required, treatment may be repeated at 14-day intervals up to a further three times. In accordance with good veterinary practice, treatment of pyoderma should be extended beyond complete resolution of clinical signs.

Severe infections of the gingival and periodontal tissues in dogs:

A single subcutaneous injection.

Skin and soft tissue abscesses and wounds in cats:

A single subcutaneous injection. If required, an additional dose may be administered 14 days after the first injection.

Urinary tract infections in dogs and cats:

A single subcutaneous injection.

**9. ADVICE ON CORRECT ADMINISTRATION**

The reconstituted solution is clear and practically free from particles. It is light yellow to reddish brown in colour.

As with other cephalosporins, the colour of the reconstituted solution may darken. However, if stored as recommended, potency is not affected.

To ensure a correct dosage, body weight should be determined as accurately as possible.

**10. WITHDRAWAL PERIODS**

Not applicable.

**11. SPECIAL STORAGE PRECAUTIONS**

Keep out of the sight and reach of children.

Before reconstitution:

Store in a refrigerator (2 °C – 8 °C). Do not freeze.  
Store in the original package in order to protect from light.

After reconstitution:

Store in a refrigerator (2 °C – 8 °C). Do not freeze.  
Store in the original package in order to protect from light.

Do not use this veterinary medicinal product after the expiry date which is stated on the label and carton.

Shelf life after reconstitution according to directions: 28 days.

## **12. SPECIAL PRECAUTIONS FOR DISPOSAL**

Medicines should not be disposed of via wastewater .  
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.  
Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required. These measures should help to protect the environment.

## **13. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS**

Veterinary medicinal product subject to prescription.

## **14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES**

Vm 42058/5016

Cardboard box with 1 glass vial of powder (containing either 390.55 mg or 978.65 mg powder for solution for injection) and 1 glass vial of solvent (containing either 4.45 or 10.8 ml solvent).

Not all pack sizes may be marketed.

## **15. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST REVISED**

[Find](#) more product information by searching for the 'Product Information Database' or 'PID' on [www.gov.uk](http://www.gov.uk).

## **16. CONTACT DETAILS**

Marketing authorisation holder:

Zoetis UK Limited  
1st Floor, Birchwood Building  
Springfield Drive  
Leatherhead  
Surrey  
KT22 7LP

Manufacturer responsible for batch release:

Haupt Pharma Latina S.r.l.  
S.S. 156 Km 47,600  
04100 Borgo San Michele  
Latina  
ITALY

**17. OTHER INFORMATION**

Cefovecin is a third-generation cephalosporin with a broad-spectrum of activity against Gram-positive and Gram-negative bacteria. It differs from other cephalosporins in that it is highly protein bound and has a long duration of activity. As with all cephalosporins, the action of cefovecin results from the inhibition of bacterial cell wall synthesis; cefovecin has bactericidal activity.

*Gavin Hall*

Approved: 11 March 2025